Lymphoma of the skin: how 6 newer drugs compare, with response rates from 34% to 69%
☕ Includes a question for the family ↓
LymphomaPart of a story we are following · 2 articles · See every update
If a rash that looks harmless turns out to be lymphoma, the next question is which treatment fits you. A big new review helps answer it. It lined up six newer drugs for cutaneous T-cell lymphoma, a lymphoma that starts in the skin, and showed that they work for many people, but not equally well for everyone.
This lymphoma is a cancer of immune cells called T cells that settle in the skin. The two main forms are mycosis fungoides and Sézary syndrome. Early on, it can look like a stubborn rash for years. In advanced disease, there can be widespread skin lesions, itching and infections. Until now, nobody had put the newer drugs side by side.
How the study worked
Researchers searched three major medical databases up to April 10, 2026. They gathered 41 studies covering 1660 patients, with an average age of about 62. Each study tested a targeted or immune-based drug used on its own. The team combined the results to estimate how many patients responded to each one. The drugs were compared across different studies, not head to head, and some studies were small, so treat the numbers as a guide. The review appeared Oct. 28, 2026, in JAMA Dermatology.
What they found
A “response” means the disease shrank or improved with treatment. Here is how the drugs lined up:
- Brentuximab vedotin: about 7 in 10 patients responded (69%).
- Interferon alfa: about 7 in 10 (68%), from a much smaller group of patients.
- Alemtuzumab: about 2 in 3 (65%).
- Mogamulizumab: close to half (45%).
- Denileukin diftitox: about 4 in 10 (39%).
- Pembrolizumab: about 1 in 3 (34%).
The type of lymphoma mattered too. In mycosis fungoides, response rates ran from 38% to 66% depending on the drug. In Sézary syndrome, they ran from 60% to 74%.
Responses lasted a median of about 5 to 9 months (4.7 to 9.4 months), depending on the drug. The median time before the disease progressed was about 14 to 23 months (14.4 to 23.3 months).
Serious side effects, grade 3 or higher, also differed. They ranged from 15% with mogamulizumab to 26% with denileukin diftitox.
So which drug is for whom?
The review does not crown one winner. The best choice depends on three things: your subtype, how long a response is likely to last, and which side effects you and your doctor are willing to weigh. A drug with the highest response rate is not automatically the best fit if another one lasts longer or is gentler on your body. That is why the authors point to individualized treatment.
What you can do today
If you or someone close to you has this lymphoma, write three questions on a card for the next visit: Which subtype is it? How often do people with this subtype respond to the options I’m being offered? How long do responses last, and what side effects should I expect? If you have a rash that has not healed after months of treatment, add a fourth: should I have a skin biopsy?
Talk about it at home
Some cells in our body are like tiny guards that patrol everywhere, and the skin has its own patrol too. Scientists lined up six medicines that doctors use to calm a problem with those guards in the skin. They found that each one helped some people, and some helped more often than others.
Question for the table
The scientists could not test all six medicines side by side in one big group. Instead they gathered many smaller studies and compared them. What could get mixed up when you compare results from different studies, and how would you plan a fairer test?
Keep exploring
Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.
Questions and answers
- What is cutaneous T-cell lymphoma?
- It is a cancer of T cells, a type of immune cell, that settles in the skin. The main forms are mycosis fungoides and Sézary syndrome.
- Which drug had the highest response rate?
- Brentuximab vedotin, with about 69% of patients responding. Interferon alfa was close at 68%, but from a smaller group.
- Do the drugs work the same in every subtype?
- No. Response rates ranged from 38% to 66% in mycosis fungoides and from 60% to 74% in Sézary syndrome.
- How long do the responses last?
- A median of about 5 to 9 months, depending on the drug. Time before progression was about 14 to 23 months.
